Staidson BioPharm(SZ:300204) IPO日报·2025-09-11 00:33Core Viewpoint - Shuyatain plans to raise up to 1.253 billion yuan through a private placement, with 883 million yuan allocated for innovative drug research and 370 million yuan for working capital [1][2]. Fund Allocation - 88% of the raised funds will be invested in research and development (883 million yuan), while the remaining 370 million yuan will be used to supplement working capital [2]. Company Operations - The company aims to ensure daily operations and enhance risk resistance through the working capital, while focusing on long-term profitability through innovative drug development [3]. Financial Situation - As of December 31, 2023, the company's fundraising account had only 70,650 yuan left, indicating an urgent need for funding during a critical phase of innovative drug development [6]. Research Pipeline - Shuyatain is a biotech firm focused on developing therapeutic drugs for unmet clinical needs, with a pipeline targeting four major areas: infectious diseases, respiratory and critical care, autoimmune diseases, and neurological disorders [6]. Key Drug Development - The drug STSP-0601 (Bomitase α) is a treatment for hemophilia and is the first global coagulation factor X activator, showing a 12-hour hemostatic rate of 81.94% in IIb phase trials [7][8]. Market Potential - The estimated peak sales for STSP-0601 could reach between 2 billion to 8 billion yuan, filling a domestic market gap and potentially enjoying a 3 to 5-year market exclusivity if approved [8]. Stock Performance - Shuyatain's stock price surged from 7.17 yuan per share on January 2 to 56.70 yuan on August 26, marking a 690.79% increase, earning it the title of "first妖股" in the pharmaceutical sector for 2025 [10]. Financial Decline - Despite the stock surge, the company's fundamentals are concerning, with a 31.14% year-on-year decline in revenue to 126 million yuan in the first half of 2025 and a net loss of 24.64 million yuan, marking five consecutive years of losses [12]. Product Sales - The main products, Su Tai Sheng and Shu Tai Qing, have seen declining sales, with Su Tai Sheng generating 74.32 million yuan (down 5.71%) and Shu Tai Qing 41.69 million yuan (down 57.88%) in the first half of 2025 [14]. R&D Investment - The company's R&D expenses decreased significantly from 412 million yuan in 2023 to 107 million yuan in 2024, raising concerns about the sustainability of its research efforts [14].